Randal Richardson
Neurology with Special Qualifications in Child Neurology · Saint Paul, MNNPI 1740397538
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $66,984 of the $88,711 with a category attached, or 75.5%. 10 manufacturers reported payments, led by Sarepta Therapeutics, Inc. at 52.1% of the total. Among neurology with special qualifications in child neurology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 101 payments — averaging $878.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$46K
- Biogen$19K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$12K
- Genentech USA, Inc.$4K
- Novartis$4K
- Genentech, Inc.$2K
- plus $2K from 4 others
Across 41 payments — averaging $14,336 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$519K
- Genentech, Inc.$50K
- Novartis$12K
- Sarepta Therapeutics, Inc.$4K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$3K
- Medtronic$613
What the payments were for
- Consulting fees$66,98476%
- Speaking & faculty fees$12,67114%
- Travel & lodging$6,8838%
- Food & beverage$1,3171%
- Education$8571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 45 | $46,253 |
| Biogen | 16 | $19,011 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 14 | $12,078 |
| Genentech USA, Inc. | 2 | $3,625 |
| Novartis | 3 | $3,536 |
| Genentech, Inc. | 16 | $1,908 |
| NS Pharma, Inc. | 2 | $1,695 |
| Vertex | 1 | $325 |
| Alnylam Pharmaceuticals Inc. | 1 | $258 |
| Medtronic | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$88,711 in reported general payments places this provider in the 95th percentile of 34 neurology with special qualifications in child neurology providers in Minnesota.
See all neurology with special qualifications in child neurology providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amondys-45Casimersen | 38 | $2,264,136 |
| EvrysdiRisdiplam | 62 | $1,817,182 |
| SkyclarysOmaveloxolone | 49 | $1,554,995 |
| EmflazaDeflazacort | 24 | $298,779 |
| Gabapentin | 43 | $1,710 |
| LevocarnitineLevocarnitine (With Sugar) | 11 | $793 |
| Topiramate | 20 | $556 |
| Amitriptyline Hcl | 12 | $410 |
| Baclofen | 25 | $332 |
| Pregabalin | 25 | $301 |
| Duloxetine Hcl | 18 | $291 |
| Tizanidine Hcl | 19 | $158 |
| Zolpidem Tartrate | 13 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sarepta Therapeutics, Inc.Amondys-45 | $46,253 | $2,264,13638 claims |
| Genentech USA, Inc.Evrysdi | $3,625 | $1,817,18262 claims |
| BiogenSkyclarys | $19,011 | $1,554,99549 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 34 neurology with special qualifications in child neurology providers in Minnesota.
Other neurology with special qualifications in child neurology in Saint Paul
- Nitin AgarwalSaint Paul$64K
- Jason DoescherSaint Paul$17K
- Dimitrios ArkiloSaint Paul$8K
- Jamie EskuriSaint Paul$6K
- Michael FrostSaint Paul$3K
- Charbel El KosseifiSaint Paul$200
- Elizabeth GillesSaint Paul$27
- Nicole DoonanSaint Paul$0
- Timothy FeymaBloomington$109K
- Douglas SmithRoseville$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.